Search - tctmd.com

Displaying 221 - 240 of 371

Sort: Relevancy | Date

News Daily News

Delaying Noncardiac Surgery for 6 Months After Coronary Stenting May Reduce Complications

L.A. McKeown

January 12, 2015

News Industry News

Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg

January 04, 2015

News Daily News

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Salynn Boyles

December 15, 2014

News Daily News

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

December 14, 2014

News Conference News AHA 2014

Long-Term Better than Short-Term Prasugrel After PES Stenting

November 15, 2014

News Daily News

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

Caitlin E. Cox

October 24, 2014

News Daily News

DCB在原发性病变中的表现比在再狭窄股腘动脉病变中更好

Caitlin E. Cox

October 24, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

News Industry News

The Lutonix® 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease

October 10, 2014

News Conference News TCT 2014

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

September 13, 2014

News Industry News

Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014

September 10, 2014

News Conference News ESC 2014

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Todd Neale

August 30, 2014

News Industry News

Boston Scientific Receives CE Mark For Agent™ Drug-Coated Balloon

July 23, 2014

News Industry News

Boston Scientific Receives CE Mark For Ranger™ Drug-Coated Balloon

July 14, 2014

News Daily News

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

L.A. McKeown

June 17, 2014

News Daily News

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

L.A. McKeown

June 17, 2014

News Industry News

Medtronic Submits Final Data to FDA for Novel Device to Treat Peripheral Artery Disease

June 11, 2014

News Daily News

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

May 30, 2014

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

Advertisement

Delaying Noncardiac Surgery for 6 Months After Coronary Stenting May Reduce Complications

Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

Long-Term Better than Short-Term Prasugrel After PES Stenting

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

DCB在原发性病变中的表现比在再狭窄股腘动脉病变中更好

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

The Lutonix® 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Boston Scientific Receives CE Mark For Agent™ Drug-Coated Balloon

Boston Scientific Receives CE Mark For Ranger™ Drug-Coated Balloon

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Medtronic Submits Final Data to FDA for Novel Device to Treat Peripheral Artery Disease

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content